Cite
HARVARD Citation
Kapoor, R. et al. (2018). Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet neurology. 17 (5), pp. 405-415. [Online].